brd2 (Santa Cruz Biotechnology)
Santa Cruz Biotechnology is a verified supplier 
92
Structured Review
Santa Cruz Biotechnology
brd2
Brd2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 28 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/brd2/BRD2+Antibody/pmc12828559-7-0-2
Average 92 stars, based on 28 article reviews
Brd2, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 28 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/brd2/BRD2+Antibody/pmc12828559-7-0-2
Average 92 stars, based on 28 article reviews
brd2 - by Bioz Stars,
2026-10
92/100 stars
Images
1) Product Images from "BRD3 PROTAC degrader targets H3K18ac to alleviate retinal microglia-driven uveitis"
Article Title: BRD3 PROTAC degrader targets H3K18ac to alleviate retinal microglia-driven uveitis
Journal: iScience
doi: 10.1016/j.isci.2025.114526
Figure Legend Snippet: D072 exerts anti-inflammatory effects by specifically degrading BRD3 (A) The expressions of BRD2, BRD3, and BRD4 in control group, EAU group, and D072 treatment group of the retina. (B) The in vitro expression of BRD2, BRD3, and BRD4 under the intervention of the ubiquitin pathway. (C) Molecular docking of BRD3 and BRD4. (D) After knockdown of BRD3 in BV2 cells, the protein expression levels of INOS, COX2, and Galectin-3 receptor in response to LPS stimulation were measured. (A) Upper: representative western blot images of retinal BRD2, BRD3, and BRD4 in Control group, EAU+Vehicle group, and EAU+D072 group, respectively. Lower: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA). (B) Left: representative western blot images of BRD2, BRD3, and BRD4 in each group in BV2. Right: quantification of the relative changes of the left ( n = 3/group; mean ± SD; ∗∗∗p < 0.001; one-way ANOVA). (C) The binding modes of BRD3 and BRD4 with D072. (D) Western blotting analysis of the protein levels of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Left: representative western blot images of iNOS, COX-2, Galectin-3, and BRD3 in different groups. Right: quantification of the relative fold changes of the left ( n = 3/group; mean ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001; one-way ANOVA).
Techniques Used: Control, In Vitro, Expressing, Ubiquitin Proteomics, Knockdown, Western Blot, Binding Assay
Related Articles
other:Article Title: BRD3 PROTAC degrader targets H3K18ac to alleviate retinal microglia-driven uveitis Article Snippet: Western Blot:Article Title: Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator cooperativity. Article Snippet: The bromodomain and extraterminal domain (BET) family of proteins are critical chromatin readers that bind to acetylated histones through their bromodomains to activate transcription.. Here, we reveal that bromodomain inhibition fails to repress oncogenic targets of estrogen receptor because of an intrinsic transcriptional mechanism.. While bromodomains are necessary for the transcription of many genes, bromodomain-containing protein 4 (BRD4) binds to estrogen receptor binding sites and activates transcription of critical oncogenes such as MYC, independently of its bromodomains. Chromatin Immunoprecipitation:Article Title: Resistance of estrogen receptor function to BET bromodomain inhibition is mediated by transcriptional coactivator cooperativity. Article Snippet: The bromodomain and extraterminal domain (BET) family of proteins are critical chromatin readers that bind to acetylated histones through their bromodomains to activate transcription.. Here, we reveal that bromodomain inhibition fails to repress oncogenic targets of estrogen receptor because of an intrinsic transcriptional mechanism.. While bromodomains are necessary for the transcription of many genes, bromodomain-containing protein 4 (BRD4) binds to estrogen receptor binding sites and activates transcription of critical oncogenes such as MYC, independently of its bromodomains. Blocking Assay:Article Title: Inhibition of Brd4 alleviates osteoarthritis pain via suppression of neuroinflammation and activation of Nrf2-mediated antioxidant signalling. Article Snippet: Funding information National Natural Science Foundation of China, Grant/Award Numbers: 82001198, 82071556, 82101310, 82271291; National Key Research and Development Program of China, Grant/Award Number: 2020YFC2005303 Abstract Background and Purpose: Osteoarthritis (OA) pain remains a major clinical problem.. It is urgent to identify novel therapeutic approaches for OA pain states.. Bromodomain and extra-terminal (BET) protein inhibitors have robust anti-inflammatory effects in several pain models. Incubation:Article Title: Inhibition of Brd4 alleviates osteoarthritis pain via suppression of neuroinflammation and activation of Nrf2-mediated antioxidant signalling. Article Snippet: Funding information National Natural Science Foundation of China, Grant/Award Numbers: 82001198, 82071556, 82101310, 82271291; National Key Research and Development Program of China, Grant/Award Number: 2020YFC2005303 Abstract Background and Purpose: Osteoarthritis (OA) pain remains a major clinical problem.. It is urgent to identify novel therapeutic approaches for OA pain states.. Bromodomain and extra-terminal (BET) protein inhibitors have robust anti-inflammatory effects in several pain models. Article Title: Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1. Article Snippet: .. After washing in PBS, sections were incubated for 1 h with |
